Patient Characteristics; Tumor Stage on FIGO, PET/CT, and PET/MRI; and Impact on Clinical Management
| Patient no. | Age (y) | FIGO stage | PET/CT stage | PET/MRI stage | Imaging comments | Change in clinical management? (PET/CT vs. PET/MRI) |
| 1 | 61 | IIB (involving vaginal fornix, with suspected parametrial involvement) | IVB (T2A N0 M1) | IVB (T2B N0 M1) | M1, paraaortic LN, on both modalities | No (both IVB); concurrent chemotherapy with cisplatin, EBRT to pelvis, and interstitial brachytherapy |
| 2 | 55 | IIB (extending into parametrium and upper third of vagina) | IIIB (T2A N1 M0) | IIIB (T2B N1 M0) | MRI detection of parametrial involvement, T2B | No (both IIIB); concurrent chemotherapy with cisplatin, pelvic EBRT, and intracavitary brachytherapy |
| 3 | 76 | IIB (involving parametrium, without sidewall involvement) | IIA (T2A N0 M0) | IIB (T2B N0 M0) | MRI detection of parametrial involvement, T2B | No (IIA vs. IIB); concurrent chemotherapy with cisplatin, pelvic EBRT, and intracavitary brachytherapy |
| 4 | 60 | IIB (involving upper third of vagina and parametrium) | IB (T1B N0 M0) | IIB (T2B N0 M0) | MRI detection of parametrial involvement, T2B | Yes; radical hysterectomy with pelvic nodal dissection (IB) vs. concurrent chemotherapy with cisplatin, pelvic EBRT, and intracavitary brachytherapy (IIB) |
| 5 | 49 | IIB (extending into right fornix and right parametrium) | IB (T1B N0 M0) | IIB (T2B N0 M0) | MRI detection of parametrial involvement, T2B | Yes; radical hysterectomy with pelvic nodal dissection (IB) vs. concurrent chemotherapy with cisplatin, pelvic EBRT, and intracavitary brachytherapy (IIB) |
| 6 | 36 | IIIB (involving parametrium with extension to pelvic sidewall) | IIB (T2B N0* M0) | IVB (T2B N0 M1) | MRI detection of peritoneal involvement, M1 | Yes; concurrent chemotherapy with cisplatin, pelvic EBRT, and intracavitary brachytherapy (IIB) vs. interstitial brachytherapy (IVB) |
↵* N0 (focal ureter activity falsely denoted as N1 on PET/CT).
EBRT = external-beam radiotherapy.